12 Best Healthcare Stocks to Buy Under $30
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities ...
Abcellera Biologics Inc. (ABCL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 27,525,640 | $94,412,945 | 0.92% | |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 4,070,300 | $13,961,129 | +54% | 0.03% |
| 3. | Millennium Management Israel Englander | 3,397,589 | $11,653,730 | +291% | 0.01% |
| 4. | OrbiMed Advisors Samuel Isaly | 3,344,568 | $11,471,868 | -21% | 0.29% |
| 5. | Renaissance Technologies Jim Simons | 3,307,429 | $11,344,481 | +15% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.16 | 343,631 | $742,242.96 | 56,143,640 | 2025-03-11 | Filing | |
| $2.30 | 25,000 | $57,500.00 | 171,000 | 2025-03-10 | Filing | |
| $2.34 | 60,000 | $140,568.00 | 146,000 | 2025-03-06 | Filing | |
| $2.61 | 283,516 | $739,976.76 | 56,086,009 | 2024-08-29 | Filing | |
| $4.46 | 10,000 | $44,600.00 | 86,000 | 2023-11-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.93 | 137,351 | $2,325,352.43 | 128,862 | 2021-09-01 | Filing | |
| $16.95 | 162,649 | $2,756,900.55 | 266,213 | 2021-08-31 | Filing | |
| $25.50 | 100,000 | $2,550,000.00 | 1,003,397 | 2021-06-22 | Filing | |
| $24.03 | 5,598,420 | $134,530,032.60 | 55,604,330 | 2021-06-09 | Filing | |
| $25.50 | 401,580 | $10,240,290.00 | 233,500 | 2021-06-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,361,096 | $45,828,559 | 0.01% | |
| 2. | 10,360,004 | $35,534,813 | 0.03% | |
| 3. | 8,471,619 | $29,057,653 | 0.01% | |
| 4. | 4,110,852 | $14,100,222 | 0.02% | |
| 5. | 4,105,095 | $14,080,476 | 0.25% |
News See All
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AbCellera's Second Quarter 2025 Business Update Conference Call. My name is Jason, and I'll facilitate the audio portion of today's interactive broadcast.
Piper Sandler Reiterates a Buy Rating on AbCellera Biologics (ABCL)
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best biotech penny stocks to buy right now. On July 28, Piper Sandler analyst Allison Bratzel maintained a Buy rating on AbCellera Biologics Inc.
14 Best Biotech Penny Stocks to Buy Right Now
He acknowledged that biotech has been a “super tough sector” either way, as there are hundreds of publicly traded stocks that do not add up to anything in aggregate.
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on ABCL.
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now.
11 Best High Return Penny Stocks to Buy Now
US equity markets are back at all-time highs amid a muted response to new U.S. tariffs and the trade war. The Nasdaq Composite Index, performing relatively well among major U.S.
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential.
13 Stocks Under $5 With High Upside Potential
On July 1, Ralph Schlosstein, Evercore chairman emeritus and BlackRock co-founder, appeared on CNBC's 'Closing Bell Overtime' to discuss his outlook for markets heading into the second half of 2025.
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential.
Billionaire Hedge Funds
